ArticleDiscover oncology2025
Identification of biomarkers related to the progression of cutaneous melanoma and construction of survival prognosis model.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUnder certain circumstances, nevi may undergo malignant transformation into skin cutaneous melanoma (SKCM), which is a highly aggressive and deadly malignant tumor originating from melanocytes. Early identification of important genes in the development of nevus into melanoma, timely treatment and blocking of the disease process can effectively reduce the occurrence of melanoma.
methodsSix datasets were downloaded from Gene Expression Omnibus with the keywords "nevus and melanoma". Differentially expressed genes (DEGs) in nevu vs. normal and melanoma vs. nevus were identified. WGCNA was used to identify disease status-related modules. Mfuzz clustering algorithm was used to select DEGs with different expression modes. PPI network was used for hub gene identification, followed by prognostic model construction, and immune microenvironment analysis. Finally, the expression of crucial genes in the process of SKCM was validated by RT-qPCR.
resultsTotally, 269 overlapped DEGs were filtered in two comparison groups. After comparing with module genes obtained from WGCNA, 159 overlapped genes were screened, which were clustered into 3 expression trend clusters. Through PPI network analysis, 26 hub genes were selected and then 5 signature genes (CCND2, NFASC, ENPP2, EPHA4 and SOX10) were selected for prognostic model construction. The samples were divided into two risk groups. Thirteen immune cell types were found to have significant difference distribution between risk groups. The consistent rate of the identified crucial hub genes between RT-qPCR and bioinformatics analyses was 100%, which showed the relatively high reliability of our bioinformatic analyses.
conclusionCCND2, NFASC, ENPP2, EPHA4 and SOX10 were identified to be candidate markers during melanoma progression. The proposed prognostic model had good predictive precision, which may be used for clinical prediction of melanoma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.